logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yu Jung Kim

Seoul National University Bundang Hospital
H指数:46
被引数:8,912

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study
Frontiers in Immunology
IF5.9
2026-07-250
OA
MK Miso Kim; EM Elizabeth M. Gaughan; AA Agueda Azpeitia; AR Aparna Rao; ML Maria L. Wei; AS Alexandra So; XZ Xiaochen Zhong; CB Carola Berking; RJ Ruixuan Jiang; SD Stéphane Dalle; CR Caroline Robert; SA Salma Alam; TD Tessa Davies; DD Dirk Debus; MD Marcin Dzienis; SD Sarah Danson; RF Ricky Frazer; CG Christoffer Gebhardt; GG Glenn Geidel; JC Jessica C. Hassel; IH Inga Hansen; MV Markus V. Heppt; LH Lina Hildebrandt; JI James Isaacs; KJ Koung Jin Suh; BK Bhumsuk Keam; YJ Yu Jung Kim; TL Thierry Lesimple; PS Phillipe Saiag; RW Ryan Weight; AD Alicia Delibes; RB Rosemarie Barnett; CK Clemens Krepler; KG Kavita Gandhi; NQ Nawab Qizilbash; IS Irene Shui; XT Xiang-Lin Tan; RJ Ryan J. Sullivan
Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD

度鲁妥单抗联合依托泊苷-铂类方案用于表皮生长因子受体（EGFR）突变型晚期非小细胞肺癌（NSCLC）并在接受奥希替尼一线治疗后发生神经内分泌转化的患者：ORCHARD研究

Lung Cancer
IF4.4
2026-06-180
PRE
Isamu Okamoto; Byoung Chul Cho; Sarah B. Goldberg; Jonathan W. Goldman; Adrianus J. de Langen; Zofia Piotrowska; Jonathan W. Riess; Helena A. Yu; MRosario Garcia Campelo; Jeremy Cetnar; Yu Jung Kim; Silvia Novello; Yoshimasa Shiraishi; Helen Ambrose; Paul E. Smith; Kwan Ho Tang; Jonathan M. Lehman; Xiuning Le
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD

奥希替尼联合达妥普玛单抗德鲁克斯特坎治疗既往一线奥希替尼进展的EGFR突变晚期非小细胞肺癌：ORCHARD研究

Annals of Oncology
IF65.4
2026-03-020
PREAI
J.W. Riess; H.A. Yu; X. Le; A.J. de Langen; B.C. Cho; Z. Piotrowska; L.E.L. Hendriks; A. Morabito; L. Bonanno; O.T. Brustugun; T.O. Halvorsen; Y.J. Kim; K.A. Marrone; Y. Shiraishi; J.W. Goldman; H. Ambrose; P.E. Smith; P.G. FraenkeI; K.H. Tang; J.M. Lehman
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Lung Cancer
IF4.4
2026-02-040
PRE
Hidetoshi Hayashi; Byoung Chul Cho; Yu Jung Kim; Se-Hoon Lee; Pongwut Danchaivijitr; Adlinda Alip; Hailin Xiong; Soon-Hin How; Gee-Chen Chang; James Chih-Hsin Yang; Yuta Yamanaka; Mehmet Ali Nahit Şendur; Kumar Prabhash; Koichi Azuma; Alianu Akawung; Elizabeth Fennema; Xiaodan Tang; Sujay Shah; Seema Sethi; Shun Lu
Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital

在三级教学医院中针对老年癌症患者开展肿瘤-老年干预模型的可行性初步研究

Cancer Research and Treatment
IF3.8
2026-01-010
OA
Kim, Jin Won; Choi, Jung-Yeon; Park, Woochan; Kang, Minsu; Seo, Jeongmin; Jung, Eun Hee; Suh, Koung Jin; Kim, Ji-Won; Kim, Se Hyun; Kim, Yu Jung; Lee, Keun-Wook; Kim, Sang-A; Lee, Ji Yun; Lee, Jeong-Ok; Bang, Soo-Mee; Kim, Kwang-il; Kim, Jee Hyun
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and leptomeningeal metastases: The KCSG LU 21-01, LAZARUS study

拉泽替尼联合培美曲塞治疗表皮生长因子受体突变阳性非小细胞肺癌合并软脑膜转移的II期研究：KCSG LU 21-01、LAZARUS研究

Lung Cancer
IF4.4
2025-11-010
PRE
Hyun-Ae Jung; Tae Min Kim; Hye Ryun Kim; Chang Gon Kim; Hee Kyung Ahn; Youngjoo Lee; Yu Jung Kim; Miso Kim; Jeonghwan Youk; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Dong-Wan Kim; Myung-Ju Ahn; Bhumsuk Keam
Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis From MARIPOSA

拉泽替尼与奥希替尼在先前未经治疗的EGFR突变晚期NSCLC中的比较: 来自MARIPOSA的随机，双盲，探索性分析

Journal of Thoracic Oncology
IF20.8
2025-07-030
OAAI
Se-Hoon Lee; Shun Lu; Hidetoshi Hayashi; Enriqueta Felip; Alexander I. Spira; Nicolas Girard; Yu Jung Kim; Yurii Ostapenko; Pongwut Danchaivijitr; Baogang Liu; Adlinda Alip; Ernesto Korbenfeld; Josiane Mourão Dias; Ki Hyeong Lee; Hailin Xiong; Soon Hin How; Ying Cheng; Gee-Chen Chang; James Chih-Hsin Yang; Benjamin Besse; Michael Thomas; Sujay Shah; Mahadi Baig; Joshua C. Curtin; Jiarui Zhang; John Xie; Tao Sun; Seema Sethi; Miao Wang; Elizabeth Fennema; Mahesh Daksh; Mariah Ennis; Joshua M. Bauml; Byoung Chul Cho
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma

早期生长反应1作为PD-L1表达和免疫逃逸的关键调节因子在结外NK/T细胞淋巴瘤中的作用

Blood Cancer Journal
IF11.6
2025-06-130
OAAI
Ji Yun Lee; Kui-Jin Kim; Woochan Park; Jeongmin Seo; Minsu Kang; Eun Hee Jung; Sang-A Kim; Koung Jin Suh; Ji-Won Kim; Se Hyun Kim; Jeong-Ok Lee; Jin Won Kim; Yu Jung Kim; Keun-Wook Lee; Jee Hyun Kim; Soo-Mee Bang; Tae Min Kim; Jin Ho Paik
Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer

转移性胃癌患者接受姑息性二线紫杉醇联合雷莫芦单抗治疗前后血浆游离DNA的配对分析

GASTRIC CANCER
IF5.1
2025-03-270
OA
Kim, Ji-Won; Kyung, Dong Soo; Ko, Won Yeong; Kim, Hwang-Phill; Hwang, Sung-Hyun; Kim, Kui-Jin; Lee, Ju Hyun; Seo, Jeongmin; Kang, Minsu; Jung, Eun Hee; Suh, Koung Jin; Kim, Se Hyun; Kim, Jin Won; Kim, Yu Jung; Kim, Jee Hyun; Lee, Keun-Wook
Preventing Infusion-Related Reactions With Intravenous Amivantamab—Results From SKIPPirr, a Phase 2 Study: A Brief Report

预防静脉注射Amivantamab相关反应：SKIPPirr一项2期研究的成果——简报

Journal of Thoracic Oncology
IF20.8
2025-01-240
OAAI
Alexander I. Spira; Luis Paz-Ares; Ji-Youn Han; Jin-Yuan Shih; Céline Mascaux; Upal Basu Roy; Jon Zugazagoitia; Yu Jung Kim; Chao-Hua Chiu; Sang-We Kim; Ernest Nadal; Ignacio Gil-Bazo; Sean P. Murphy; Bailey G. Anderson; Yichuan Xia; George Wang; Joshua M. Bauml; Marc Chioda; Jairo Simoes; Parthiv J. Mahadevia; Gilberto Lopes
Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital
SCIENTIFIC REPORTS
IF3.9
2025-01-160
OAAI
Kim, Jin Won; Na, Hee Young; Lee, Sejoon; Kim, Ji-Won; Suh, Koung Jin; Kim, Se Hyun; Kim, Yu Jung; Lee, Keun-Wook; Lee, Jong Seok; Kim, Jaihwan; Hwang, Jin-Hyeok; Hwang, Kihwan; Kim, Chae-Yong; Kim, Yong Beom; Ahn, Soomin; Lee, Kyu Sang; Kim, Hyojin; Lee, Hye Seung; Park, So Yeon; Choe, Gheeyoung; Kim, Jee Hyun; Chung, Jin-Haeng
Association of TP53 Mutation Status and Sex with Clinical Outcome in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study

TP53突变状态与性别对接受免疫检查点抑制剂治疗的非小细胞肺癌患者临床结局的影响：一项回顾性队列研究

CANCER RESEARCH AND TREATMENT
IF3.8
2025-01-151
OA
Choi, Songji; Kim, Se Hyun; Lee, Sejoon; Seo, Jeongmin; Kang, Minsu; Jung, Eun Hee; Kim, Sang-A; Suh, Koung Jin; Lee, Ji Yun; Kim, Ji-Won; Kim, Jin Won; Lee, Jeong-Ok; Kim, Yu Jung; Lee, Keun-Wook; Kim, Jee Hyun; Bang, Soo-Mee; Lee, Jong Seok
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Amivantamab联合lazertinib与osimertinib治疗具有高危疾病生物标志物的一线EGFR突变晚期非小细胞肺癌: 来自MARIPOSA的二次分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-015
OAAI
Felip, E.; Cho, B. C.; Gutierrez, V; Alip, A.; Besse, B.; Lu, S.; Spira, A. I.; Girard, N.; Califano, R.; Gadgeel, S. M.; Yang, J. C-H.; Yamamoto, S.; Azuma, K.; Kim, Y. J.; Lee, K. -H.; Danchaivijitr, P.; Ferreira, C. G.; Cheng, Y.; Sendur, M. A. N.; Chang, G. -C.; Wang, C. -C.; Prabhash, K.; Shinno, Y.; Stroyakovskiy, D.; Paz-Ares, L.; Rodriguez-Cid, J. R.; Martin, C.; Campelo, M. R. G.; Hayashi, H.; Nguyen, D.; Tomasini, P.; Gottfried, M.; Dooms, C.; Passaro, A.; Schuler, M.; Gelatti, A. C. Z.; Owen, S.; Perdrizet, K.; Ou, S. -H. I.; Curtin, J. C.; Zhang, J.; Gormley, M.; Sun, T.; Panchal, A.; Ennis, M.; Fennema, E.; Bauml, J. M.; Daksh, M.; Sethi, S.; Lee, S. -H.

研究方向

暂未获取到该数据
J
Jee Hyun Kim
H 指数:53论文数:491被引数:1.4万
S
Se Hyun Kim
H 指数:41论文数:384被引数:7,653
K
Keun‐Wook Lee
H 指数:55论文数:483被引数:1.5万
J
Jong Seok Lee
H 指数:42论文数:215被引数:1.1万
K
Koung Jin Suh
H 指数:23论文数:199被引数:2,265
J
Jin Won Kim
H 指数:45论文数:508被引数:9,515
S
Soo‐Mee Bang
H 指数:42论文数:480被引数:7,687
J
Ji‐Won Kim
H 指数:29论文数:263被引数:3,282
J
Jeong‐Ok Lee
H 指数:30论文数:244被引数:3,501
B
Bhumsuk Keam
H 指数:63论文数:696被引数:1.7万